---
layout: default
title: Venetoclax
parent: Model Prediction Only (L5)
nav_order: 963
evidence_level: L5
indication_count: 10
---

# Venetoclax
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Venetoclax: From Its Currently Labeled Indications to CLL/SLL with IGHV Somatic Hypermutation

## One-Sentence Summary

Venetoclax is a selective BCL-2 inhibitor, marketed in Canada as VENCLEXTA. The Evidence Pack does not list its original labeled indications.
The TxGNN model predicts it may be effective for **chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with IGHV somatic hypermutation**.
For this specific subtype, **0 clinical trials** and **0 publications** were retrieved, so the prediction currently rests on the model score and biological rationale alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in the Evidence Pack (Canadian license entries contain no indication text) |
| Predicted New Indication | CLL/SLL with immunoglobulin heavy chain variable-region gene somatic hypermutation |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 4 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Venetoclax selectively inhibits BCL-2, an anti-apoptotic protein. It is a BH3 mimetic that restores programmed cell death in malignant cells. CLL/SLL cells typically overexpress BCL-2, so the biological rationale for this prediction is strong. Detailed mechanism-of-action data were not available in the drug record, so this reasoning comes from the prediction's mechanistic-link notes.

The predicted indication is a molecular subtype of CLL/SLL (mutated IGHV), not a separate disease. Literature in the pack on other indications describes venetoclax as highly efficacious in CLL and an approved standard of care in frontline and relapsed disease with anti-CD20 antibodies. If the parent CLL/SLL indication is already on the Canadian label, this may not be repurposing in the strict sense. The Evidence Pack contains no indication text, so the labeled status must be confirmed first.

The high TxGNN score is a knowledge-graph prediction only. It is not clinical evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this specific subtype.

---

## Literature Evidence

Currently no related literature available for this specific subtype.

---

## Canada Market Information

| DIN | Product Name |
|---------|------|
| 2458055 | VENCLEXTA |
| 2458047 | VENCLEXTA |
| 2458063 | VENCLEXTA |
| 2458039 | VENCLEXTA |

Dosage form and approved indication text were not provided for these four authorizations.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BCL-2 inhibitor, BH3 mimetic) |
| Myelosuppression Risk | Medium to high. Published reviews identify myelosuppression and tumour lysis syndrome as the most commonly encountered toxicities |
| Emetogenicity Classification | Low (oral targeted agent; please confirm against the package insert) |
| Monitoring Items | CBC with differential, renal function and electrolytes (tumour lysis syndrome risk), liver function |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information. No interaction records were found for this drug in the queried sources.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has a strong mechanistic basis, but no trials or publications support this IGHV-mutated CLL/SLL subtype. Safety documents and the original indications are also missing, so the evidence cannot yet support advancing it.

**To proceed, the following is needed:**
- Health Canada package insert (warnings, contraindications) for VENCLEXTA, and confirmation of the labeled status of the parent CLL/SLL indication
- Original indication and mechanism-of-action data for the drug record (for example from DrugBank)
- A subtype-specific literature and trial search for CLL/SLL by IGHV mutation status
- Review of the other predicted indications in the pack. For example, myeloid leukemia has Phase 2 trial support (L2, Proceed with Guardrails) and may be a better first focus

*This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

